Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial

View ORCID ProfileRaburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
doi: https://doi.org/10.1101/2021.12.23.21267374
Raburn Mallory
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raburn Mallory
  • For correspondence: RMallory@novavax.com
Neil Formica
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Pfeiffer
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bethanie Wilkinson
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Marcheschi
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Albert
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather McFall
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Robinson
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce S. Plested
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingzhu Zhu
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane Cloney-Clark
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Zhou
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon Chau
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreana Robertson
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia Maciejewski
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gale Smith
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nita Patel
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory M. Glenn
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filip Dubovsky
Novavax, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Novavax, Inc
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

SUMMARY

Background Emerging SARS-CoV-2 variants and evidence of waning vaccine efficacy present significant obstacles toward controlling the COVID-19 pandemic. Booster doses of SARS-CoV-2 vaccines may address these concerns by both amplifying and broadening the immune responses seen with initial vaccination regimens.

Methods In a phase 2 study, a single booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M™ adjuvant (NVX-CoV2373) was administered to healthy adult participants 18 to 84 years of age approximately 6 months following their primary two-dose vaccination series. Safety and immunogenicity parameters were assessed, including assays for IgG, MN50, and hACE2 receptor binding inhibition against the ancestral SARS-CoV-2 strain and select variants (B.1.351 [Beta], B.1.1.7 [Alpha], B.1.617.2 [Delta], and B.1.1.529 [Omicron]). This trial is registered with ClinicalTrials.gov, NCT04368988.

Findings An incremental increase in the incidence of solicited local and systemic reactogenicity events was observed with subsequent vaccinations. Following the booster, incidence rates of local and systemic reactions were 82.5% (13.4% ≥ Grade 3) and 76.5% (15.3% ≥ Grade 3), respectively, compared to 70.0% (5.2% ≥ Grade 3) and 52.8% (5.6% ≥ Grade 3), respectively, following the primary vaccination series. Events were primarily mild or moderate in severity and transient in nature, with a median duration of 1.0 to 2.5 days. Immune responses seen 14 days following the primary vaccination series were compared with those observed 28 days following the booster (Day 35 and Day 217, respectively). For the ancestral SARS-CoV-2 strain, serum IgG geometric mean titers (GMTs) increased ∼4.7-fold from 43,905 ELISA units (EU) at day 35 to 204,367 EU at Day 217. Neutralization (MN50) assay GMTs showed a similar increase of ∼4.1-fold from 1,470 at day 35 to 6,023 at Day 217. A functional hACE2 receptor binding inhibition assay analyzing activity against ancestral and variant strains of SARS-CoV-2 at Day 189 vs Day 217 found 54.4-fold (Ancestral), 21.9-fold (Alpha), 24.5-fold (Beta), 24.4-fold (Delta), and 20.1-fold (Omicron) increases in titers. An anti-rS IgG activity assay comparing the same time points across the same SARS-CoV-2 strains found titers improved 61.2-fold, 85.9-fold, 65.0-fold, 92.5-fold, and 73.5-fold, respectively.

Interpretation Administration of a booster dose of NVX-CoV2373 approximately 6 months following the primary vaccination series resulted in an incremental increase in reactogenicity along with enhanced immune responses. For both the prototype strain and all variants evaluated, immune responses following the booster were notably higher than those associated with high levels of efficacy in phase 3 studies of the vaccine.

Funding Novavax® and the Coalition for Epidemic Preparedness Innovations (CEPI®).

Competing Interest Statement

Disclosure forms provided by the authors will be available with the full text of this article upon publication.

Clinical Trial

NCT04368988

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT04368988

Funding Statement

This study was funded by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial protocol was approved by the Alfred Hospital Human Research Ethics Committee (Melbourne, Australia) and Advarra Central Institutional Review Board (Colombia, Maryland, USA) and was performed in accordance with the International Conference on Harmonisation, Good Clinical Practice guidelines. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data Availability Data Sharing Statement will be available with the full text of this article upon publication.

https://clinicaltrials.gov/ct2/show/NCT04368988

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 25, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Raburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
medRxiv 2021.12.23.21267374; doi: https://doi.org/10.1101/2021.12.23.21267374
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Raburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
medRxiv 2021.12.23.21267374; doi: https://doi.org/10.1101/2021.12.23.21267374

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (162)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (863)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8573)
  • Forensic Medicine (4)
  • Gastroenterology (388)
  • Genetic and Genomic Medicine (1759)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1250)
  • Health Policy (622)
  • Health Systems and Quality Improvement (469)
  • Hematology (196)
  • HIV/AIDS (378)
  • Infectious Diseases (except HIV/AIDS) (10319)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (213)
  • Neurology (1682)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (264)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (254)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1775)
  • Public and Global Health (3854)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)